Providing anti-retroviral treatment did not achieve the ambition of 'Joint united nations program on HIV/AIDS (UNAIDS) among HIV positive patient in Ethiopia': a systematic review and meta-analysis.

IF 3.3 Q1 HEALTH POLICY & SERVICES

Journal of Pharmaceutical Policy and Practice Pub Date : 2023-12-27 eCollection Date: 2024-01-01 DOI:10.1080/20523211.2023.2290672

Tamirat Melis, Tadesse Sahle, Kassahun Haile, Abebe Timerga, Amare Zewdie, Yohannes Wegu, Kebebush Zepire, Jemal Bedewi

{"title":"Providing anti-retroviral treatment did not achieve the ambition of 'Joint united nations program on HIV/AIDS (UNAIDS) among HIV positive patient in Ethiopia': a systematic review and meta-analysis.","authors":"Tamirat Melis, Tadesse Sahle, Kassahun Haile, Abebe Timerga, Amare Zewdie, Yohannes Wegu, Kebebush Zepire, Jemal Bedewi","doi":"10.1080/20523211.2023.2290672","DOIUrl":null,"url":null,"abstract":"Introduction: Antiretroviral Treatment (ART) has great importance in reducing viral load. Though a global effort was made to suppress viral load, the level of viral load suppression among ART patients is still high in Ethiopia.Objective: This study aims to assess the magnitude and contributing factors for viral load suppression among patients attending ART clinics in Ethiopia.Methods: The articles were searched using different databases using the guideline of reporting systematic review and meta-analysis (PRISMA). A random effect model was used to ascertain the pooled prevalence of viral load suppression in Ethiopia using STATA 14 software.Results: The pooled prevalence of suppressed viral load was 75.25% (95% CI: 68.61-81.89). Having good adherence (OR: 2.71, 95% CI 2.27, 3.15), baseline CD4 count (OR: 1.74, 95% CI 1.53, 1.96), and being female (OR: 1.41, 95% CI 1.04, 1.79) were determinants of pooled estimates of suppressed viral load.Conclusion: The pooled prevalence of suppressed viral load was 75% which is lower than the targeted level by the sustainable development goal (SDG) 2020, which was 90%. Therefore, the stakeholders should be focused on the existing strategies to decrease viral load among ART patients. They should work to adhere to patients for ART treatment.","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"17 1","pages":"2290672"},"PeriodicalIF":3.3000,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10793635/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Policy and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20523211.2023.2290672","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Antiretroviral Treatment (ART) has great importance in reducing viral load. Though a global effort was made to suppress viral load, the level of viral load suppression among ART patients is still high in Ethiopia.

Objective: This study aims to assess the magnitude and contributing factors for viral load suppression among patients attending ART clinics in Ethiopia.

Methods: The articles were searched using different databases using the guideline of reporting systematic review and meta-analysis (PRISMA). A random effect model was used to ascertain the pooled prevalence of viral load suppression in Ethiopia using STATA 14 software.

Results: The pooled prevalence of suppressed viral load was 75.25% (95% CI: 68.61-81.89). Having good adherence (OR: 2.71, 95% CI 2.27, 3.15), baseline CD4 count (OR: 1.74, 95% CI 1.53, 1.96), and being female (OR: 1.41, 95% CI 1.04, 1.79) were determinants of pooled estimates of suppressed viral load.

Conclusion: The pooled prevalence of suppressed viral load was 75% which is lower than the targeted level by the sustainable development goal (SDG) 2020, which was 90%. Therefore, the stakeholders should be focused on the existing strategies to decrease viral load among ART patients. They should work to adhere to patients for ART treatment.

查看原文本刊更多论文

提供抗逆转录病毒治疗并未实现 "联合国艾滋病规划署（UNAIDS）在埃塞俄比亚艾滋病毒阳性患者中的联合计划 "的目标：系统回顾和荟萃分析。

简介抗逆转录病毒治疗（ART）对降低病毒载量具有重要意义。尽管全球都在努力抑制病毒载量，但在埃塞俄比亚，抗逆转录病毒疗法患者的病毒载量抑制水平仍然很高：本研究旨在评估埃塞俄比亚抗逆转录病毒疗法门诊患者病毒载量抑制的程度和诱因：采用系统综述和荟萃分析报告指南（PRISMA）在不同数据库中检索文章。使用 STATA 14 软件，采用随机效应模型确定埃塞俄比亚病毒载量抑制的总体流行率：病毒载量抑制的总体流行率为 75.25%（95% CI：68.61-81.89）。良好的依从性（OR：2.71，95% CI：2.27，3.15）、基线 CD4 细胞数（OR：1.74，95% CI：1.53，1.96）和女性（OR：1.41，95% CI：1.04，1.79）是病毒载量被抑制的集合估计值的决定因素：病毒载量得到抑制的总体流行率为 75%，低于可持续发展目标（SDG）2020 的目标水平（90%）。因此，利益相关方应关注现有的降低抗逆转录病毒疗法患者病毒载量的策略。他们应努力使患者坚持接受抗逆转录病毒疗法治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Pharmaceutical Policy and Practice Health Professions-Pharmacy

CiteScore

4.70

自引率

9.50%

发文量

审稿时长

14 weeks